MDT

97.6

-1.71%↓

A

148.9

+1.14%↑

VEEV

242.56

-0.54%↓

HQY

95.52

-1.95%↓

PHR.US

17.28

+1.23%↑

MDT

97.6

-1.71%↓

A

148.9

+1.14%↑

VEEV

242.56

-0.54%↓

HQY

95.52

-1.95%↓

PHR.US

17.28

+1.23%↑

MDT

97.6

-1.71%↓

A

148.9

+1.14%↑

VEEV

242.56

-0.54%↓

HQY

95.52

-1.95%↓

PHR.US

17.28

+1.23%↑

MDT

97.6

-1.71%↓

A

148.9

+1.14%↑

VEEV

242.56

-0.54%↓

HQY

95.52

-1.95%↓

PHR.US

17.28

+1.23%↑

MDT

97.6

-1.71%↓

A

148.9

+1.14%↑

VEEV

242.56

-0.54%↓

HQY

95.52

-1.95%↓

PHR.US

17.28

+1.23%↑

Search

Exact Sciences Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

102.12 0.41

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

101.68

Max

102.15

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-18M

-20M

Pardavimai

40M

851M

Pelno marža

-2.303

Darbuotojai

6,900

EBITDA

-17M

48M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

-1.55% downside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-18

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

6.6B

19B

Ankstesnė atidarymo kaina

101.71

Ankstesnė uždarymo kaina

102.12

Naujienos nuotaikos

By Acuity

50%

50%

190 / 372 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Exact Sciences Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-20 13:14; UTC

Įsigijimai, susijungimai, perėmimai

Correction to Abbott to Acquire Exact Sciences for $21 Billion Article

2025-11-20 13:11; UTC

Įsigijimai, susijungimai, perėmimai

Abbott to Acquire Exact Sciences for $21 Billion -- Update

2025-11-20 12:55; UTC

Įsigijimai, susijungimai, perėmimai

Abbott to Acquire Exact Sciences for $21 Billion

2025-11-20 16:51; UTC

Įsigijimai, susijungimai, perėmimai

Abbott Laboratories Will Buy Cologuard Maker Exact Sciences for $21 Billion -- Barrons.com

2025-11-20 15:08; UTC

Įsigijimai, susijungimai, perėmimai

Abbott to Acquire Exact Sciences for $21 Billion -- 4th Update

2025-11-20 14:39; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Abbott and Exact Sciences Should Make a Good Fit -- Market Talk

2025-11-20 14:30; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Exact Sciences Should Give Abbott's Diagnostics Business a Needed Boost -- Market Talk

2025-11-20 13:51; UTC

Įsigijimai, susijungimai, perėmimai

Abbott to Acquire Exact Sciences for $21 Billion -- 3rd Update

2025-11-20 13:25; UTC

Įsigijimai, susijungimai, perėmimai

Abbott to Acquire Exact Sciences for $21 Billion -- 2nd Update

2025-11-20 13:24; UTC

Įsigijimai, susijungimai, perėmimai

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. -- Barrons.com

2025-11-20 12:59; UTC

Įsigijimai, susijungimai, perėmimai

Correction to Abbott to Acquire Exact Sciences for $21B Article

2025-11-20 12:58; UTC

Įsigijimai, susijungimai, perėmimai

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. -- Barrons.com

2025-11-20 12:56; UTC

Įsigijimai, susijungimai, perėmimai

Abbott to Acquire Exact Sciences for $21B -- Update

2025-11-20 12:54; UTC

Įsigijimai, susijungimai, perėmimai

Abbott Labs: Expect to Maintain Investment-Grade Credit Rating >ABT EXAS

2025-11-20 12:53; UTC

Įsigijimai, susijungimai, perėmimai

Abbott Labs to Fund Exact Sciences Deal With Cash on Hand, Debt Financing >ABT EXAS

2025-11-20 12:53; UTC

Įsigijimai, susijungimai, perėmimai

Abbott Labs Sees Exact Sciences Deal Adding to Adjusted EPS in 2028, Beyond >ABT EXAS

2025-11-20 12:53; UTC

Įsigijimai, susijungimai, perėmimai

Abbott Labs Sees Exact Sciences Deal Cutting Adjusted EPS by 20c in 2026, 16c in 2027 >ABT EXAS

2025-11-20 12:52; UTC

Įsigijimai, susijungimai, perėmimai

Abbott Labs Sees at Least $100 Million Annual Pretax Synergies From Exact Sciences Deal by 2028 >ABT EXAS

2025-11-20 12:46; UTC

Įsigijimai, susijungimai, perėmimai

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. -- Barrons.com

2025-11-20 12:40; UTC

Įsigijimai, susijungimai, perėmimai

Abbott to Acquire Exact Sciences for $21B

2025-11-20 12:33; UTC

Įsigijimai, susijungimai, perėmimai

Abbott Labs: Exact Sciences Deal Has Enterprise Value of About $23 Billion >ABT EXAS

2025-11-20 12:33; UTC

Įsigijimai, susijungimai, perėmimai

Exact Sciences to Be Acquired for $105/Share; Closed Wednesday at $86.18 >ABT EXAS

2025-11-20 12:32; UTC

Įsigijimai, susijungimai, perėmimai

Abbott Labs Sees Acquisition Immediately Adding to Revenue Growth, Gross Margin >ABT EXAS

2025-11-20 12:31; UTC

Įsigijimai, susijungimai, perėmimai

Abbott Labs: Exact Sciences Deal Has Total Equity Value of About $21 Billion >ABT EXAS

2025-11-20 12:30; UTC

Įsigijimai, susijungimai, perėmimai

Abbott to Buy Exact Sciences for $105/Share >ABT EXAS

2025-11-20 12:30; UTC

Įsigijimai, susijungimai, perėmimai

Abbott To Acquire Exact Sciences, A Leader In Large And Fast-growing Cancer Screening And Precision Oncology Diagnostics Segments >ABT

2025-11-19 21:27; UTC

Įsigijimai, susijungimai, perėmimai

Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Exact Sciences Corp Prognozė

Kainos tikslas

By TipRanks

-1.55% į apačią

12 mėnesių prognozė

Vidutinis 100.2 USD  -1.55%

Aukščiausias 105 USD

Žemiausias 78 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Exact Sciences Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

20 ratings

1

Pirkti

19

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

45.6 / 54.37Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

190 / 372 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Exact Sciences Corp

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
help-icon Live chat